Salvinorin A inhibits colonic transit and neurogenic ion transport in mice by activating κ-opioid and cannabinoid receptors

Neurogastroenterology and Motility

Volumn 21, Issue 12, 2009, Pages

  Fichna, J ^a,b   Schicho, R ^a   Andrews, C N ^a   Bashashati, M ^c   Klompus, M ^c   McKay, D M ^c   Sharkey, K A ^c   Zjawiony, J K ^d   Janecka, A ^b   Storr, M A ^a  

^a Division of Gastroenterology   (Canada)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

Cannabinoid receptors; Gastrointestinal tract; Ion transport; Kappa opioid receptor; Motility; Mouse colon; Salvinorin A

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; CANNABINOID RECEPTOR; FORSKOLIN; KAPPA OPIATE RECEPTOR; NALOXONE; NORBINALTORPHIMINE; SALVINORIN A; VERATRIDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; COLON; COLON MUCOSA; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; GASTROINTESTINAL MOTILITY; ILEUM; IN VITRO STUDY; IN VIVO STUDY; INTESTINE MOTILITY; INTESTINE TRANSIT TIME; ION TRANSPORT; MALE; MOUSE; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; STOMACH; STOMACH EMPTYING; UPPER GASTROINTESTINAL TRACT;

ANIMALS; COLON; DITERPENES, CLERODANE; ELECTRIC STIMULATION; GASTRIC EMPTYING; GASTROINTESTINAL TRANSIT; ION TRANSPORT; MALE; MICE; MUSCLE, SMOOTH; PSYCHOTROPIC DRUGS; RECEPTORS, CANNABINOID; RECEPTORS, OPIOID, KAPPA;

EID: 72449196776     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2009.01369.x     Document Type: Article

References (45)

1. Roth BL, Baner K, Westkaemper R et al. Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci USA 2002 99 : 11934 11939.
2. Dhawan BN, Cesselin F, Raghubir R et al. International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol Rev 1996 48 : 567 592.
3. Shippenberg TS, Chefer VI, Zapata A, Heidbreder CA. Modulation of the behavioral and neurochemical effects of psychostimulants by kappa-opioid receptor systems. Ann N Y Acad Sci 2001 937 : 50 73.
4. Lokensgard JR, Gekker G, Peterson PK. Kappa-opioid receptor agonist inhibition of HIV-1 envelope glycoprotein-mediated membrane fusion and CXCR4 expression on CD4(+) lymphocytes. Biochem Pharmacol 2002 63 : 1037 1041.
5. Bohn LM, Belcheva MM, Coscia CJ. Mitogenic signaling via endogenous kappa-opioid receptors in C6 glioma cells: evidence for the involvement of protein kinase C and the mitogen-activated protein kinase signaling cascade. J Neurochem 2000 74 : 564 573.
6. Chamouard P, Klein A, Martin E, Adloff M, Angel F. Regulatory role of enteric kappa opioid receptors in human colonic motility. Life Sci 1993 53 : 1149 1156.
7. Schreiber R, Bartoszyk GD, Kunzelmann K. The kappa-opioid receptor agonist asimadoline inhibits epithelial transport in mouse trachea and colon. Eur J Pharmacol 2004 503 : 185 190.
8. Hicks GA, Haven-Hudkins DL, Camilleri M. Opiates in the control of gastrointestinal tract function: current knowledge and new avenues for research. Neurogastroenterol Motil 2004 16 (Suppl. 2 67 70.
9. Sengupta JN, Su X, Gebhart GF. Kappa, but not mu or delta, opioids attenuate responses to distention of afferent fibers innervating the rat colon. Gastroenterology 1996 111 : 968 980.
10. Jimenez N, Puig MM, Pol O. Antiexudative effects of opioids and expression of kappa- and delta-opioid receptors during intestinal inflammation in mice: involvement of nitric oxide. J Pharmacol Exp Ther 2006 316 : 261 270.
11. Delgado-Aros S, Chial HJ, Camilleri M et al. Effects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans. Am J Physiol Gastrointest Liver Physiol 2003 284 : G558 66.
12. Camilleri M. Novel pharmacology: asimadoline, a kappa-opioid agonist, and visceral sensation. Neurogastroenterol Motil 2008 20 : 971 979.
13. Capasso R, Borrelli F, Capasso F et al. The hallucinogenic herb Salvia divinorum and its active ingredient salvinorin A inhibit enteric cholinergic transmission in the guinea-pig ileum. Neurogastroenterol Motil 2006 18 : 69 75.
14. Capasso R, Borrelli F, Zjawiony J et al. The hallucinogenic herb Salvia divinorum and its active ingredient salvinorin A reduce inflammation-induced hypermotility in mice. Neurogastroenterol Motil 2008 20 : 142 148.
15. Capasso R, Borrelli F, Cascio MG et al. Inhibitory effect of salvinorin A, from Salvia divinorum, on ileitis-induced hypermotility: cross-talk between kappa-opioid and cannabinoid CB(1) receptors. Br J Pharmacol 2008 155 : 681 689.
16. Storr M, Hahn A, Gaffal E, Saur D, Allescher HD. Effects of endomorphin-1 and -2 on mu-opioid receptors in myenteric neurons and in the peristaltic reflex in rat small intestine. Clin Exp Pharmacol Physiol 2002 29 : 428 434.
17. O'Hara JR, Lomax AE, Mawe GM, Sharkey KA. Ileitis alters neuronal and enteroendocrine signalling in guinea pig distal colon. Gut 2007 56 : 186 194.
18. Sibaev A, Yuce B, Kemmer M et al. Cannabinoid-1 (CB1) receptors regulate colonic propulsion by acting at motor neurons within the ascending motor pathways in mouse colon. Am J Physiol Gastrointest Liver Physiol 2009 296 : G119 28.
19. Smits GJ, Lefebvre RA. Influence of aging on gastric emptying of liquids, small intestine transit, and fecal output in rats. Exp Gerontol 1996 31 : 589 596.
20. Capasso R, Matias I, Lutz B et al. Fatty acid amide hydrolase controls mouse intestinal motility in vivo. Gastroenterology 2005 129 : 941 951.
21. Chavkin C, Sud S, Jin W et al. Salvinorin A, an active component of the hallucinogenic sage Salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations. J Pharmacol Exp Ther 2004 308 : 1197 1203.
22. Mule F, Amato A, Baldassano S, Serio R. Involvement of CB1 and CB2 receptors in the modulation of cholinergic neurotransmission in mouse gastric preparations. Pharmacol Res 2007 56 : 185 192.
23. Mule F, Amato A, Baldassano S, Serio R. Evidence for a modulatory role of cannabinoids on the excitatory NANC neurotransmission in mouse colon. Pharmacol Res 2007 56 : 132 139.
24. Imanshahidi M, Hosseinzadeh H. The pharmacological effects of Salvia species on the central nervous system. Phytother Res 2006 20 : 427 437.
25. Ansonoff MA, Zhang J, Czyzyk T et al. Antinociceptive and hypothermic effects of Salvinorin A are abolished in a novel strain of kappa-opioid receptor-1 knockout mice. J Pharmacol Exp Ther 2006 318 : 641 648.
26. Hyland NP, Cox HM. The regulation of veratridine-stimulated electrogenic ion transport in mouse colon by neuropeptide Y (NPY), Y1 and Y2 receptors. Br J Pharmacol 2005 146 : 712 722.
27. Braida D, Limonta V, Capurro V et al. Involvement of kappa-opioid and endocannabinoid system on Salvinorin A-induced reward. Biol Psychiatry 2008 63 : 286 292.
28. Braida D, Limonta V, Pegorini S et al. Hallucinatory and rewarding effect of salvinorin A in zebrafish: kappa-opioid and CB1-cannabinoid receptor involvement. Psychopharmacology (Berl) 2007 190 : 441 448.
29. Smith PB, Welch SP, Martin BR. Interactions between delta 9-tetrahydrocannabinol and kappa opioids in mice. J Pharmacol Exp Ther 1994 268 : 1381 1387.
30. Giuliani S, Lecci A, Tramontana M, Maggi CA. Role of kappa opioid receptors in modulating cholinergic twitches in the circular muscle of guinea-pig colon. Br J Pharmacol 1996 119 : 985 989.
31. Duncan M, Mouihate A, Mackie K et al. Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated rats. Am J Physiol Gastrointest Liver Physiol 2008 295 : G78 87.
32. Coutts AA, Irving AJ, Mackie K, Pertwee RG, navi-Goffer S. Localisation of cannabinoid CB(1) receptor immunoreactivity in the guinea pig and rat myenteric plexus. J Comp Neurol 2002 448 : 410 422.
33. Sternini C, Patierno S, Selmer IS, Kirchgessner A. The opioid system in the gastrointestinal tract. Neurogastroenterol Motil 2004 16 (Suppl. 2 3 16.
34. Kulkarni-Narla A, Brown DR. Opioid, cannabinoid and vanilloid receptor localization on porcine cultured myenteric neurons. Neurosci Lett 2001 308 : 153 156.
35. Hojo M, Sudo Y, Ando Y et al. mu-Opioid receptor forms a functional heterodimer with cannabinoid CB1 receptor: electrophysiological and FRET assay analysis. J Pharmacol Sci 2008 108 : 308 319.
36. Henry DJ, Grandy DK, Lester HA, Davidson N, Chavkin C. Kappa-opioid receptors couple to inwardly rectifying potassium channels when coexpressed by Xenopus oocytes. Mol Pharmacol 1995 47 : 551 557.
37. McAllister SD, Griffin G, Satin LS, Abood ME. Cannabinoid receptors can activate and inhibit G protein-coupled inwardly rectifying potassium channels in a xenopus oocyte expression system. J Pharmacol Exp Ther 1999 291 : 618 626.
38. Blednov YA, Stoffel M, Alva H, Harris RA. A pervasive mechanism for analgesia: activation of GIRK2 channels. Proc Natl Acad Sci USA 2003 100 : 277 282.
39. Anand U, Otto WR, Sanchez-Herrera D et al. Cannabinoid receptor CB2 localisation and agonist-mediated inhibition of capsaicin responses in human sensory neurons. Pain 2008 138 : 667 680.
40. Hohmann AG, Herkenham M. Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience 1999 92 : 1171 1175.
41. Bi J, Tsai NP, Lu HY, Loh HH, Wei LN. Copb1-facilitated axonal transport and translation of kappa opioid-receptor mRNA. Proc Natl Acad Sci USA 2007 104 : 13810 13815.
42. Gebhart GF, Su X, Joshi S, Ozaki N, Sengupta JN. Peripheral opioid modulation of visceral pain. Ann NY Acad Sci 2000 909 : 41 50.
43. Coutts AA, Pertwee RG. Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig myenteric plexus. Br J Pharmacol 1997 121 : 1557 1566.
44. Eisenach JC, Carpenter R, Curry R. Analgesia from a peripherally active kappa-opioid receptor agonist in patients with chronic pancreatitis. Pain 2003 101 : 89 95.
45. Hooker JM, Xu Y, Schiffer W, Shea C, Carter P, Fowler JS. Pharmacokinetics of the potent hallucinogen, salvinorin A in primates parallels the rapid onset and short duration of effects in humans. Neuroimage 2008 41 : 1044 1050.